B
Barbara A. Goff
Researcher at University of Washington
Publications - 235
Citations - 12862
Barbara A. Goff is an academic researcher from University of Washington. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 61, co-authored 227 publications receiving 11859 citations. Previous affiliations of Barbara A. Goff include Georgetown University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Preoperative angiographic uterine artery embolization in the management of cervical pregnancy.
TL;DR: Two cases of cervical pregnancy detected by ultra-sound were reported, and the uterine arteries were successfully embolized using angiographic techniques, and surgical evacuation was performed with minimal hemorrhage; hysterectomy was not required and the patients' potential fertility was retained.
Journal ArticleDOI
Immunophenotype of Ovarian Cancer as Predictor of Clinical Outcome: Evaluation at Primary Surgery and Second-Look Procedure
TL;DR: The only tumor markers to predict for response to chemotherapy were p53 at initial surgery and Ki67 indices at secondary surgery, and expression of steroid hormone receptors, TNFalpha, and P-glycoprotein and overexpression of c-erb-B-2 or EGFR are not associated with chemoresistance.
Journal Article
Telomerase activation in cervical cancer
Suzanne Anderson,Katherine A. Shera,Jennifer Ihle,Lisa Billman,Barbara A. Goff,Benjamin E. Greer,Hisham Tamimi,James K. McDougall,Aloysius J. Klingelhutz +8 more
TL;DR: Results indicate that telomerase activation is common in high-grade cervical cancers and suggests that telomersase activity may be a useful diagnostic marker for the disease.
Journal ArticleDOI
Trends in treatment of advanced epithelial ovarian cancer in the Medicare population.
Melissa M. Thrall,Heidi J. Gray,Rebecca Gaston Symons,Noel S. Weiss,David R. Flum,Barbara A. Goff +5 more
TL;DR: The majority of women with advanced ovarian cancer in the Medicare population do not receive both combination therapy with surgery and at least 6 cycles of chemotherapy, and the majority of these patients do not have cancer-directed surgery.
Journal ArticleDOI
Alterations in SPARC and VEGF Immunoreactivity in Epithelial Ovarian Cancer
TL;DR: Results indicate the possibility of an aberration in the interaction that has been described in normal endothelium between SPARC and VEGF in association with malignant transformation, with a distinct distribution of SPARC in the stroma of neoplastic ovaries and V EGF within tumor cells.